Search Bar & Filters
Found 18 Actively Recruiting clinical trials
Actively Recruiting
This research aims to find out if intismeran autogene combined with pembrolizumab can stop the growth or spread of advanced melanoma, a type of skin cancer that has spread to other parts of the body and cannot be removed by surgery. The study compares this combination to a placebo with pembrolizumab to see if people live longer without their cancer worsening. Immunotherapy, which helps the immune system fight cancer, is the standard treatment for advanced melanoma. Participants in the study will be randomly assigned to receive either intismeran autogene by intramuscular injection every three weeks for up to nine doses plus pembrolizumab by intravenous infusion every six weeks for up to 17 doses or until the disease progresses or they stop treatment. Alternatively, they will receive a placebo injection on the same schedule plus pembrolizumab. The total treatment duration can last up to about two years. During the study, participants will be monitored for cancer progression and survival for up to about three years for progression-free survival and up to six years for other outcomes including overall response and survival. Researchers will collect tumor tissue samples for genetic and biomarker analyses and assess safety by tracking adverse events and treatment discontinuations. The study involves regular visits for treatments and assessments throughout the treatment period and follow-up monitoring.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, best dose, and how the body processes a drug called BNT326 alone and combined with other immunotherapies in people with advanced solid tumors. These tumors are either metastatic, recurrent, or have progressed despite prior treatments. The study includes multiple specific tumor types and is divided into two parts, each enrolling participants independently to assess BNT326 alone or with other drugs like pumitamig. Participants in Part 1 receive BNT326 alone in different groups based on their tumor type, including cutaneous melanoma, non-small cell lung cancer, rare melanomas, cervical cancer, and other solid tumors. Part 2 studies BNT326 alone or combined with pumitamig for various cancers such as melanoma, breast cancer, gastric cancer, colorectal cancer, and cervical cancer. Some groups involve random assignment to different dose levels, while others do not. Treatments are given via intravenous infusion or oral administration depending on the drug. Participants undergo a screening period followed by treatment lasting up to 24 months or until disease progression, consent withdrawal, study end, or unacceptable side effects. After treatment, there are safety and efficacy follow-up periods, plus long-term survival tracking, with total involvement lasting about 38 months for Part 1 and 48 months for Part 2. Researchers monitor side effects, tumor response, survival, and drug levels in the blood to assess safety and activity of the treatments.
Actively Recruiting
Researchers are investigating the clinical benefits of combining RP2, a genetically modified herpes simplex virus, with nivolumab, an immune checkpoint inhibitor, in adults with metastatic uveal melanoma who have not previously received immune checkpoint inhibitor therapy. This phase 23 randomized trial compares this combination against the combination of nivolumab and ipilimumab, another immune checkpoint inhibitor, to evaluate their effects on survival and disease progression. Participants will be randomly assigned to receive either RP2 plus nivolumab or ipilimumab plus nivolumab. RP2 is designed to stimulate the immune system and directly attack tumors, while nivolumab and ipilimumab work by blocking proteins that limit immune response against cancer cells. The study treatment is administered over time, with careful monitoring of safety and effectiveness. There are no placebo groups, and the trial is open-label, meaning both participants and researchers know which treatment is given. Throughout the study, participants will undergo regular assessments to evaluate overall survival and progression-free survival for up to three years after the last treatment dose. Additional evaluations include tracking response rates and disease control every 12 weeks and monitoring for any treatment-related adverse events for up to 100 days post-treatment. Blood tests, tumor biopsies, and imaging will be part of the ongoing evaluations. Participants are expected to remain engaged with the study procedures for the duration of the follow-up period to help researchers understand the treatments impact.
Actively Recruiting
Researchers are evaluating KIN-2787, a RAF small molecule kinase inhibitor, in adults with advanced or metastatic solid tumors that have BRAF or NRAS mutations. This study aims to assess the safety, tolerability, pharmacokinetics how the drug moves through the body, and initial effects of KIN-2787 alone and in combination with binimetinib, a MEK inhibitor. The study includes patients with various cancers such as lung cancer and melanoma that contain specific BRAF mutations. The trial has two parts a dose escalation phase to find the recommended dose of KIN-2787 alone and combined with binimetinib, and a dose expansion phase to further evaluate safety and effectiveness at this dose. KIN-2787 is taken orally twice daily in 28-day cycles. In combination groups, binimetinib is also given orally twice daily either continuously or intermittently, depending on the subgroup. Participants will receive study treatments and undergo regular assessments including tumor measurements using RECIST v1.1 criteria. Researchers will monitor safety, drug levels, and response to therapy up to 18 months in dose escalation and up to approximately 36 months in dose expansion. The study measures include objective response rate, disease control, and duration of response or stable disease, with ongoing evaluations during and after treatment.
Actively Recruiting
Researchers are evaluating the combination of immunotherapy drugs ipilimumab and nivolumab with or without concurrent stereotactic radiotherapy in patients who have asymptomatic, untreated melanoma brain metastases. This phase II randomized trial aims to compare these treatments to determine their effect on neurological death rate at 12 months and assess other outcomes such as tumor response, progression-free survival, overall survival, neurocognitive function, adverse events, and quality of life. The study builds on previous findings that combining these immunotherapies is more effective than nivolumab alone and investigates how radiotherapy might boost immune responses against tumors. Participants will receive ipilimumab and nivolumab at doses approved for advanced melanoma. One group will also receive stereotactic radiotherapy to brain metastases within seven days of a baseline MRI scan. Radiotherapy doses vary by lesion size and are delivered in one or several fractions. Both groups may receive salvage therapies like surgery or radiotherapy if brain disease progresses. Treatment is administered according to a 11 randomization with stratification by factors such as brain metastases count and mutation status. During participation, patients will undergo regular MRIs, neurocognitive tests using the Montreal Cognitive Assessment, neurological exams with the NANO scale, and quality of life questionnaires including FACT-Brain and EORTC modules. Blood, tissue, stool, and urine samples will be collected for biomarker analysis. Adverse events will be monitored closely, and continued treatment beyond progression may be allowed if clinically appropriate. The study plans long-term follow-up up to 10 years to track outcomes and safety, with total participation lasting up to the study completion in 2029.
Actively Recruiting
Researchers are evaluating the combination of brenetafusp IMC-F106C plus nivolumab compared to standard nivolumab regimens in people with previously untreated advanced melanoma who are HLA-A*0201-positive. This phase 3, randomized, controlled study aims to understand how these treatments perform in this specific group. The study focuses on improving progression-free survival and overall outcomes for participants with advanced melanoma. Participants are assigned to one of three groups one group receives a low dose of brenetafusp once weekly for 13 weeks, then every two weeks until Week 51, and every four weeks thereafter, along with nivolumab every four weeks another group receives a high dose of brenetafusp on the same schedule plus nivolumab the third group receives nivolumab alone or nivolumab combined with relatlimab every four weeks. The study includes a dose recommendation phase with changes made in November 2025 based on safety and efficacy data. During the study, participants undergo assessments including tumor measurements per RECIST 1.1, BRAF V600 mutation status evaluation, and performance status scoring. Researchers will monitor progression-free survival up to approximately 45 months, overall survival up to 57 months, and record adverse events, immune responses, and quality of life. The study involves regular dosing and long-term follow-up to evaluate treatment effects and safety.
Actively Recruiting
Researchers are studying the long-term safety and effectiveness of pembrolizumab MK-3475 in participants with advanced tumors or blood cancers who were part of previous pembrolizumab-based studies. This extension study includes participants currently receiving treatment or in follow-up from parent trials. It consists of three phases the First Course Phase, Survival Follow-up Phase, and Second Course Phase, depending on the participants status at the end of their previous study. Participants may receive pembrolizumab alone or combined with standard of care treatments, lenvatinib, or other study drugs like olaparib and MK-4280, delivered mainly by intravenous infusion or oral capsules. Dosing schedules vary, including pembrolizumab administered every 3 or 6 weeks for up to 35 or 17 doses depending on the phase. Some participants may take lenvatinib orally daily, timed with pembrolizumab infusions, while others may receive investigational combination therapies or standard care treatments according to their parent studys protocol. During the study, participants will have regular infusions or oral dosing and be monitored over several years for overall survival and other outcomes like progression-free survival and adverse events. Researchers will assess safety and efficacy for up to approximately 10 years, with detailed tracking of side effects and treatment discontinuations. Study visits and assessments will be conducted to evaluate organ function, disease status, and any treatment-related effects throughout the study duration.
Actively Recruiting
Researchers are evaluating new combinations of immunotherapy for patients with resectable stage 3 cutaneous melanoma and any stage of mucosal melanoma. The study focuses on patients who can have surgery to remove all tumor deposits. The goal is to improve outcomes for patients who typically respond poorly to standard immunotherapy by testing neoadjuvant immunotherapy given before surgery to reduce recurrence. The trial tests six different immunotherapy combinations using the drugs nivolumab, relatlimab, ipilimumab, and pembrolizumab. These are given as two doses before surgery to stimulate the immune system to better attack melanoma cells. After surgery, patients may receive standard immunotherapy if the neoadjuvant treatment does not sufficiently reduce cancer cells. The study includes four phases neoadjuvant treatment, surgery, possible adjuvant therapy, and long-term follow-up for up to 10 years. Participants will undergo assessments including biomarker testing, imaging, and pathology to evaluate tumor response at six weeks. Researchers will monitor survival, recurrence, side effects, and quality of life over 10 years. The study will also explore biomarkers in blood, tumor tissue, and stool to understand treatment response. A total of 493 patients will participate in this phase II trial conducted in Australia.
Actively Recruiting
This research aims to evaluate neoadjuvant therapy using a combination of two immune checkpoint inhibitors, nivolumab and relatlimab, targeting the PD-1 and LAG-3 pathways in patients with treatment-nafve, resectable stage II to IV cutaneous squamous cell carcinoma. The study is a phase 2, open-label, single-group trial designed to assess pathological response rate and recurrence-free survival compared to historical data from monotherapy with cemiplimab. It focuses on improving outcomes in this patient population by testing dual immune checkpoint inhibition before surgery. Participants will receive two doses of a fixed dose combination of nivolumab 480 mg and relatlimab 160 mg administered by infusion on days 1 and 29 before surgery. Patients who do not achieve a complete pathological response may then receive standard radiotherapy as decided by a multidisciplinary team. This neoadjuvant treatment approach aims to enhance tumor response prior to surgical removal. During the study, participants will undergo tumor biopsies, imaging assessments, and blood tests to evaluate pathological response, toxicity, and tolerability of the therapy. Outcomes measured include pathological complete response rate at week 6, recurrence-free survival over 10 years, quality of life assessments at one year, and overall survival. Safety and completion of treatment are monitored up to week 48. The total study participation includes pre-surgery treatment followed by long-term follow-up for survival and disease recurrence.
Actively Recruiting
This research aims to evaluate neoadjuvant dual immunotherapy using nivolumab and relatlimab in patients with resectable stage I to stage III Merkel cell carcinoma. The study focuses on treatment-naefve patients and compares the pathological response rate and recurrence-free survival to historical data from nivolumab monotherapy. The trial is phase 2, open-label, and single-arm, conducted at a single center to explore the combined immune checkpoint inhibition of PD-1 and LAG-3 pathways. Participants will receive two doses of a fixed dose combination of nivolumab 480 mg and relatlimab 160 mg administered by infusion on days 1 and 29 before surgery. The treatment regimen is based on prior studies in melanoma patients and aims to assess the safety and efficacy of this dual checkpoint inhibition as neoadjuvant therapy. All enrolled participants will receive the same treatment, with no placebo or comparator group. During the study, participants will be closely monitored for pathological responses, toxicity, tolerability, and objective and metabolic responses at week 6 and week 24. The study will also track recurrence-free survival, event-free survival, overall survival, and patient-reported quality of life for up to 10 years. Surgical-related adverse events and treatment completion rates will be assessed, with overall study duration extending to long-term outcomes and safety follow-up.
1-10 of 18
1